Akero Therapeutics, Inc
Clinical trials sponsored by Akero Therapeutics, Inc, explained in plain language.
-
New drug aims to halt liver scarring in 2,150 patients with fatty liver disease
Disease control Recruiting nowThis phase 3 trial tests efruxifermin, a weekly injection, in 2,150 adults with liver scarring (cirrhosis) caused by NASH/MASH, a type of fatty liver disease. Half get the drug, half get a placebo. The goal is to see if efruxifermin can prevent serious liver events like liver fai…
Phase: PHASE3 • Sponsor: Akero Therapeutics, Inc • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
New drug shows promise in reversing liver scarring in major trial
Disease control Recruiting nowThis Phase 3 study tests a drug called efruxifermin in 1,650 people with non-cirrhotic NASH/MASH and moderate liver scarring (stage 2 or 3). Participants receive either the drug or a placebo as a weekly injection. The goal is to see if the drug can reverse liver inflammation and …
Phase: PHASE3 • Sponsor: Akero Therapeutics, Inc • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC